Consensus on the use of DPP4 Inhibitors and SGLT2 Inhibitors in T2DM with Chronic Kidney Disease-from Indian Context

Abstract

Chronic Kidney Disease and Diabetes are diseases of concern globally including developing countries like India. The delayed intervention of non-communicable disease management, the unique socioeconomic condition, etc makes chronic kidney disease a potential threat in the future. Diabetes in India plays an important role in developing CKD & its associated complications. To treat diabetes, many innovative antidiabetic agents were introduced in the last two decades. Some of these newer anti-diabetic medications have established cardio-renal safety in diabetic patients. Many endocrine and cardiovascular societies have already adopted these anti-diabetic agents into the respective algorithms. Overall for newer anti-diabetic medication, there is no available published guidance in India that has prioritized both renal safety and other parameters related to nephrology practice. A group of Indian nephrologists, after analyzing existing published evidence and guidance from different guidelines, prepared a simple common algorithm to manage diabetes patients with associated CKD. This new algorithm, having both DPP4i and SGLT2i, will surely help Indian health care professionals to manage diabetes in CKD patients, in a more efficient way.